JP2021513558A5 - - Google Patents

Info

Publication number
JP2021513558A5
JP2021513558A5 JP2020564795A JP2020564795A JP2021513558A5 JP 2021513558 A5 JP2021513558 A5 JP 2021513558A5 JP 2020564795 A JP2020564795 A JP 2020564795A JP 2020564795 A JP2020564795 A JP 2020564795A JP 2021513558 A5 JP2021513558 A5 JP 2021513558A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
hypertonic pharmaceutical
composition according
hypertonic
platinum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020564795A
Other languages
English (en)
Japanese (ja)
Other versions
JP7492917B2 (ja
JP2021513558A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/017334 external-priority patent/WO2019157370A1/en
Publication of JP2021513558A publication Critical patent/JP2021513558A/ja
Publication of JP2021513558A5 publication Critical patent/JP2021513558A5/ja
Priority to JP2024081711A priority Critical patent/JP2024098070A/ja
Application granted granted Critical
Publication of JP7492917B2 publication Critical patent/JP7492917B2/ja
Priority to JP2026077143A priority patent/JP2026119177A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020564795A 2018-02-09 2019-02-08 抗白金化学保護剤を含む高張医薬組成物 Active JP7492917B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024081711A JP2024098070A (ja) 2018-02-09 2024-05-20 抗白金化学保護剤を含む高張医薬組成物
JP2026077143A JP2026119177A (ja) 2018-02-09 2026-05-01 抗白金化学保護剤を含む高張医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862628824P 2018-02-09 2018-02-09
US62/628,824 2018-02-09
PCT/US2019/017334 WO2019157370A1 (en) 2018-02-09 2019-02-08 Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024081711A Division JP2024098070A (ja) 2018-02-09 2024-05-20 抗白金化学保護剤を含む高張医薬組成物

Publications (3)

Publication Number Publication Date
JP2021513558A JP2021513558A (ja) 2021-05-27
JP2021513558A5 true JP2021513558A5 (enExample) 2022-02-15
JP7492917B2 JP7492917B2 (ja) 2024-05-30

Family

ID=67549759

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020564795A Active JP7492917B2 (ja) 2018-02-09 2019-02-08 抗白金化学保護剤を含む高張医薬組成物
JP2024081711A Pending JP2024098070A (ja) 2018-02-09 2024-05-20 抗白金化学保護剤を含む高張医薬組成物
JP2026077143A Pending JP2026119177A (ja) 2018-02-09 2026-05-01 抗白金化学保護剤を含む高張医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024081711A Pending JP2024098070A (ja) 2018-02-09 2024-05-20 抗白金化学保護剤を含む高張医薬組成物
JP2026077143A Pending JP2026119177A (ja) 2018-02-09 2026-05-01 抗白金化学保護剤を含む高張医薬組成物

Country Status (12)

Country Link
US (5) US10709732B2 (enExample)
EP (1) EP3749309A4 (enExample)
JP (3) JP7492917B2 (enExample)
KR (1) KR102860981B1 (enExample)
CN (1) CN112020359A (enExample)
AU (1) AU2019218232B2 (enExample)
BR (1) BR112020016059A2 (enExample)
CA (1) CA3090783A1 (enExample)
IL (1) IL276569B2 (enExample)
MX (2) MX2020008323A (enExample)
SG (1) SG11202007595WA (enExample)
WO (1) WO2019157370A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018039375A1 (en) 2016-08-23 2018-03-01 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
BR112020016059A2 (pt) 2018-02-09 2020-12-08 Decibel Therapeutics, Inc. Composições farmacêuticas hipertônicas contendo um agente quimioprotetor anti-platina
IL325122A (en) 2018-02-22 2026-02-01 Akouos Inc Compositions and methods for treating non-age-related hearing impairment in humans
BR112021000021A2 (pt) * 2018-07-03 2021-03-30 Fennec Pharmaceuticals, Inc. Tiossulfato de sódio anidro e formulações do mesmo
US20220054640A1 (en) * 2018-12-11 2022-02-24 Decibel Therapeutics, Inc. Compositions and methods for the delivery of therapeutic agents across the round window membrane
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents
WO2020256548A1 (en) * 2019-06-19 2020-12-24 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Sodium thiosulfate gel for preventing or reducing hearing loss
CN114845721A (zh) * 2019-10-30 2022-08-02 奥德纳米有限公司 用于药物诱导的耳毒性的耳用制剂
CA3168055A1 (en) 2020-02-21 2021-08-26 Emmanuel John Simons Compositions and methods for treating non-age-associated hearing impairment in a human subject
US20260027327A1 (en) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Otic drug delivery system and methods

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649621B2 (en) 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6497902B1 (en) 1999-12-01 2002-12-24 The Regents Of The University Of Michigan Ionically crosslinked hydrogels with adjustable gelation time
KR20030014208A (ko) 2000-04-26 2003-02-15 오레곤 헬스 사이언시즈 유니버시티 티올계 화학보호제 화합물의 투여
EP1404689A1 (en) * 2001-07-02 2004-04-07 Debiopharm S.A. Oxaliplatin active substance with a very low content of oxalic acid
US7790699B2 (en) 2004-10-12 2010-09-07 Fmc Biopolymer As Self-gelling alginate systems and uses thereof
CA2620374C (en) 2005-09-28 2012-12-11 Thomas Meyer Pharmaceutical compositions for the treatment of inner ear disorders
WO2008056822A1 (en) 2006-11-09 2008-05-15 Takeda Pharmaceutical Company Limited Pharmaceutical composition comprising a dihydrobenzofuranyl isoindoline and a lipophilic component
WO2009132050A2 (en) * 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US20100016450A1 (en) 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
US8784870B2 (en) * 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
JP5905387B2 (ja) * 2009-07-08 2016-04-20 ホープ メディカル エンタープライゼズ,インコーポレイテッド ディービーエー ホープ ファーマシュティカルズHope Medical Enterprises,Inc.Dba Hope Pharmaceuticals チオ硫酸ナトリウムを含有する薬学的組成物
EP3501521A1 (en) 2011-02-18 2019-06-26 Otonomy, Inc. Prevention of and recovery from drug-induced ototoxicity
US10130514B2 (en) 2011-09-26 2018-11-20 Incube Labs, Llc System and method for delivery of a therapeutic agent to the inner ear
FR2992861B1 (fr) * 2012-07-09 2014-10-17 Probionov Utilisation de thiosulfate pour potentialiser l'effet anti-pathogene des lactobacilles
JP7074663B6 (ja) * 2015-05-28 2022-08-01 ベイラー カレッジ オブ メディスン グルタチオンレベルを改善するためのn-アセチルシステイン及びグリシンの補給の効果
AU2016304585B2 (en) 2015-08-05 2023-04-06 Children's Medical Center Corporation Compositions with permeation enhancers for drug delivery
US20190038756A1 (en) 2016-02-10 2019-02-07 Cocoon Biotech Inc. Compositions including benzenesulfonamide-containing non-steroidal anti-inflammatory drugs, silk fibroin, and a gelling agent and uses thereof
EP3478269A4 (en) 2016-06-29 2020-04-08 Otonomy, Inc. OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES
EP3570826A4 (en) 2017-01-19 2020-09-23 Otologic Pharmaceutics, Inc. N-ACETYLCYSTEIN FORMULATIONS AND THEIR USES
US10596190B2 (en) 2017-11-29 2020-03-24 Oregon Health & Science University Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy
WO2019118330A1 (en) 2017-12-12 2019-06-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Thermoresponsive hydrogel containing polymer microparticles for controlled drug delivery to the ear
US11918653B2 (en) 2017-12-22 2024-03-05 Dompé Farmaceutici S.P.A. Triglyceride otic formulations and uses thereof
US10946443B2 (en) 2018-01-08 2021-03-16 Hamilton Sundstrand Corporation Removal of unfused powder from an additive-manufactured part using piezoelectric transducers
WO2019140012A1 (en) 2018-01-09 2019-07-18 Otonomy, Inc. Growth factor otic formulations
WO2019154895A1 (en) 2018-02-08 2019-08-15 Strekin Ag Gel formulation for preventing or treating hearing loss
BR112020016059A2 (pt) 2018-02-09 2020-12-08 Decibel Therapeutics, Inc. Composições farmacêuticas hipertônicas contendo um agente quimioprotetor anti-platina
US20210186943A1 (en) 2018-04-25 2021-06-24 Otonomy, Inc. Otic formulations for drug-induced ototoxicity
IT201800006566A1 (it) 2018-06-21 2019-12-21 Composizione per prevenire e trattare disordini uditivi e vestibolari
BR112021000021A2 (pt) 2018-07-03 2021-03-30 Fennec Pharmaceuticals, Inc. Tiossulfato de sódio anidro e formulações do mesmo
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents
WO2020256548A1 (en) 2019-06-19 2020-12-24 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Sodium thiosulfate gel for preventing or reducing hearing loss

Similar Documents

Publication Publication Date Title
TW201717973A (zh) 無刺激性眼用聚乙烯吡咯啶酮-碘組成物
CN100341498C (zh) 含有2-氨基-3-(4-溴苯甲酰基)苯乙酸的水成液制剂
US11986491B2 (en) Pharmaceutical compositions comprising iodine and steroid and uses thereof for sinus diseases
PT739197E (pt) Composicoes de farmacos oftalmicos conservados contendo compostos de amonio quaternario polimericos
RS53598B1 (sr) Topikalni preparati za očuvanje ili ponovno uspostavljanje integriteta sluzokoža
JP2012520882A5 (enExample)
JP2013536874A (ja) 鼻腔噴霧剤
JP2017002035A5 (enExample)
JP2008024700A (ja) ベルベリン含有水性組成物
CA3042729A1 (en) In situ gel-forming pharmaceutical compositions and uses thereof for sinus diseases
CN103260616B (zh) 对乙酰氨基酚的稳定化剂
ES2301807T3 (es) Compuestos de amoniociclodextrina cuaternizados.
NO339109B1 (no) Konserverende sammensetning for oftalmisk anvendelse
JP2024512121A5 (enExample)
JP4752987B2 (ja) 外用剤組成物
JP7254101B2 (ja) 複数回使用のトラセミド組成物
JP2007522077A (ja) 粘膜の疾患および障害の予防および処置のための液体製剤
CN110785162A (zh) 用于治疗青光眼的滴眼液组合物
JP5572110B2 (ja) 粘膜の疾患および障害の予防および処置のための液体製剤
CN115137699B (zh) 一种增效防腐的右美托咪定鼻喷剂
JP4956981B2 (ja) オキシメタゾリン含有水性組成物
JP5922609B2 (ja) 2−アミノ−3−(4−ブロモベンゾイル)フェニル酢酸含有水性組成物
JP2025502242A5 (enExample)
PT1212050E (pt) Formulações contendo tetraciclinas para tratar ou evitar a mucosite
CN107820422A (zh) 包含硫辛酸和类粘液状聚合物的眼用组合物